Exact Mass: 511.1663
Exact Mass Matches: 511.1663
Found 468 metabolites which its exact mass value is equals to given mass value 511.1663
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
3-Methyl-1-hydroxybutyl-ThPP
3-Methyl-1-hydroxybutyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15974). It is the second to last step in the synthesis of 3-methylbutanoyl-CoA and is converted from 4-methyl-2-oxopentanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(3-methylbutanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. [HMDB] 3-Methyl-1-hydroxybutyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15974). It is the second to last step in the synthesis of 3-methylbutanoyl-CoA and is converted from 4-methyl-2-oxopentanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(3-methylbutanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4].
2-Methyl-1-hydroxybutyl-ThPP
2-Methyl-1-hydroxybutyl-ThPP is an intermediate in Valine, leucine and isoleucine degradation. 2-Methyl-1-hydroxybutyl-ThPP is the second to last step for the synthesis of (S)-2-Methylbutanoyl-CoA. 2-Methyl-1-hydroxybutyl-ThPP is converted from (S)-3-Methyl-2-oxopentanoic acid via the enzyme 2-oxoisovalerate dehydrogenase E1 component, alpha subunit(EC 1.2.4.4). It is then converted to S-(2-Methylbutanoyl)-dihydrolipoamide-E via the same enzyme. 2-Methyl-1-hydroxybutyl-ThPP is an intermediate in Valine, leucine and isoleucine degradation. 2-Methyl-1-hydroxybutyl-ThPP is the second to last step for the synthesis of (S)-2-Methylbutanoyl-CoA. 2-Methyl-1-hydroxybutyl-ThPP is converted
O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->3)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol
O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->3)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol is a natural oligosaccharide of human milk identified with a Mass-Spectrometry fragment spectral library (PMID: 16194087) [HMDB] O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->3)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol is a natural oligosaccharide of human milk identified with a Mass-Spectrometry fragment spectral library (PMID: 16194087).
O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->4)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol
O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->4)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol is a natural oligosaccharide of human milk identified with an Mass-Spectrometry fragment spectral library (PMID: 16194087) [HMDB] O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->4)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol is a natural oligosaccharide of human milk identified with an Mass-Spectrometry fragment spectral library (PMID: 16194087).
Cefetamet pivoxyl
2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminoethyl phosphonic acid
Hygromycin A
Raticate
3-acetyl-3,12-dihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxyhexopyranoside
Ala Met Gln Tyr
Ala Met Tyr Gln
Ala Gln Met Tyr
Ala Gln Tyr Met
Ala Tyr Met Gln
Ala Tyr Gln Met
Cys Cys Met Arg
Cys Cys Arg Met
Cys Cys Thr Trp
Cys Cys Trp Thr
Cys Asp Phe Lys
Cys Asp Phe Gln
Cys Asp Lys Phe
Cys Asp Gln Phe
Cys Glu Phe Asn
Cys Glu Asn Phe
Cys Phe Asp Lys
Cys Phe Asp Gln
Cys Phe Glu Asn
Cys Phe Gly Trp
Cys Phe Lys Asp
Cys Phe Asn Glu
Cys Phe Gln Asp
Cys Phe Trp Gly
Cys Gly Phe Trp
Cys Gly Trp Phe
Cys Ile Asn Tyr
Cys Ile Tyr Asn
Cys Lys Asp Phe
Cys Lys Phe Asp
Cys Lys Met Met
Cys Leu Asn Tyr
Cys Leu Tyr Asn
Cys Met Cys Arg
Cys Met Lys Met
Cys Met Met Lys
Cys Met Met Gln
Cys Met Gln Met
Cys Met Arg Cys
Cys Asn Glu Phe
Cys Asn Phe Glu
Cys Asn Ile Tyr
Cys Asn Leu Tyr
Cys Asn Tyr Ile
Cys Asn Tyr Leu
Cys Gln Asp Phe
Cys Gln Phe Asp
Cys Gln Met Met
Cys Gln Val Tyr
Cys Gln Tyr Val
Cys Arg Cys Met
Cys Arg Met Cys
Cys Thr Cys Trp
Cys Thr Trp Cys
Cys Val Gln Tyr
Cys Val Tyr Gln
Cys Trp Cys Thr
Cys Trp Phe Gly
Cys Trp Gly Phe
Cys Trp Thr Cys
Cys Tyr Ile Asn
Cys Tyr Leu Asn
Cys Tyr Asn Ile
Cys Tyr Asn Leu
Cys Tyr Gln Val
Cys Tyr Val Gln
Asp Cys Phe Lys
Asp Cys Phe Gln
Asp Cys Lys Phe
Asp Cys Gln Phe
Asp Phe Cys Lys
Asp Phe Cys Gln
Asp Phe Lys Cys
Asp Phe Gln Cys
Asp Lys Cys Phe
Asp Lys Phe Cys
Asp Asn Thr Tyr
Asp Asn Tyr Thr
Asp Gln Cys Phe
Asp Gln Phe Cys
Asp Gln Ser Tyr
Asp Gln Tyr Ser
Asp Ser Gln Tyr
Asp Ser Tyr Gln
Asp Thr Asn Tyr
Asp Thr Tyr Asn
Asp Tyr Asn Thr
Asp Tyr Gln Ser
Asp Tyr Ser Gln
Asp Tyr Thr Asn
Glu Cys Phe Asn
Glu Cys Asn Phe
Glu Phe Cys Asn
Glu Phe Asn Cys
Glu Asn Cys Phe
Glu Asn Phe Cys
Glu Asn Ser Tyr
Glu Asn Tyr Ser
Glu Ser Asn Tyr
Glu Ser Tyr Asn
Glu Tyr Asn Ser
Glu Tyr Ser Asn
Phe Cys Asp Lys
Phe Cys Asp Gln
Phe Cys Glu Asn
Phe Cys Gly Trp
Phe Cys Lys Asp
Phe Cys Asn Glu
Phe Cys Gln Asp
Phe Cys Trp Gly
Phe Asp Cys Lys
Phe Asp Cys Gln
Phe Asp Lys Cys
Phe Asp Gln Cys
Phe Glu Cys Asn
Phe Glu Asn Cys
Phe Gly Cys Trp
Phe Gly Trp Cys
Phe Lys Cys Asp
Phe Lys Asp Cys
Phe Met Asn Thr
Phe Met Gln Ser
Phe Met Ser Gln
Phe Met Thr Asn
Phe Asn Cys Glu
Phe Asn Glu Cys
Phe Asn Met Thr
Phe Asn Thr Met
Phe Gln Cys Asp
Phe Gln Asp Cys
Phe Gln Met Ser
Phe Gln Ser Met
Phe Ser Met Gln
Phe Ser Gln Met
Phe Thr Met Asn
Phe Thr Asn Met
Phe Trp Cys Gly
Phe Trp Gly Cys
Gly Cys Phe Trp
Gly Cys Trp Phe
Gly Phe Cys Trp
Gly Phe Trp Cys
Gly Ser Trp Tyr
Gly Ser Tyr Trp
Gly Trp Cys Phe
Gly Trp Phe Cys
Gly Trp Ser Tyr
Gly Trp Tyr Ser
Gly Tyr Ser Trp
Gly Tyr Trp Ser
His Asn Asn Gln
His Asn Gln Asn
His Gln Asn Asn
Ile Cys Asn Tyr
Ile Cys Tyr Asn
Ile Asn Cys Tyr
Ile Asn Tyr Cys
Ile Tyr Cys Asn
Ile Tyr Asn Cys
Lys Cys Asp Phe
Lys Cys Phe Asp
Lys Cys Met Met
Lys Asp Cys Phe
Lys Asp Phe Cys
Lys Phe Cys Asp
Lys Phe Asp Cys
Lys Met Cys Met
Lys Met Met Cys
Leu Cys Asn Tyr
Leu Cys Tyr Asn
Leu Asn Cys Tyr
Leu Asn Tyr Cys
Leu Tyr Cys Asn
Leu Tyr Asn Cys
Met Ala Gln Tyr
Met Ala Tyr Gln
Met Cys Cys Arg
Met Cys Lys Met
Met Cys Met Lys
Met Cys Met Gln
Met Cys Gln Met
Met Cys Arg Cys
Met Phe Asn Thr
Met Phe Gln Ser
Met Phe Ser Gln
Met Phe Thr Asn
Met Lys Cys Met
Met Lys Met Cys
Met Met Cys Lys
Met Met Cys Gln
Met Met Lys Cys
Met Met Gln Cys
Met Asn Phe Thr
Met Asn Thr Phe
Met Gln Ala Tyr
Met Gln Cys Met
Met Gln Phe Ser
Met Gln Met Cys
Met Gln Ser Phe
Met Gln Tyr Ala
Met Arg Cys Cys
Met Ser Phe Gln
Met Ser Gln Phe
Met Thr Phe Asn
Met Thr Asn Phe
Met Tyr Ala Gln
Met Tyr Gln Ala
Asn Cys Glu Phe
Asn Cys Phe Glu
Asn Cys Ile Tyr
Asn Cys Leu Tyr
Asn Cys Tyr Ile
Asn Cys Tyr Leu
Asn Asp Thr Tyr
Asn Asp Tyr Thr
Asn Glu Cys Phe
Asn Glu Phe Cys
Asn Glu Ser Tyr
Asn Glu Tyr Ser
Asn Phe Cys Glu
Asn Phe Glu Cys
Asn Phe Met Thr
Asn Phe Thr Met
Asn His Asn Gln
Asn His Gln Asn
Asn Ile Cys Tyr
Asn Ile Tyr Cys
Asn Leu Cys Tyr
Asn Leu Tyr Cys
Asn Met Phe Thr
Asn Met Thr Phe
Asn Asn His Gln
Asn Asn Gln His
Asn Gln His Asn
Asn Gln Asn His
Asn Ser Glu Tyr
Asn Ser Tyr Glu
Asn Thr Asp Tyr
Asn Thr Phe Met
Asn Thr Met Phe
Asn Thr Tyr Asp
Asn Tyr Cys Ile
Asn Tyr Cys Leu
Asn Tyr Asp Thr
Asn Tyr Glu Ser
Asn Tyr Ile Cys
Asn Tyr Leu Cys
Asn Tyr Ser Glu
Asn Tyr Thr Asp
Gln Ala Met Tyr
Gln Ala Tyr Met
Gln Cys Asp Phe
Gln Cys Phe Asp
Gln Cys Met Met
Gln Cys Val Tyr
Gln Cys Tyr Val
Gln Asp Cys Phe
Gln Asp Phe Cys
Gln Asp Ser Tyr
Gln Asp Tyr Ser
Gln Phe Cys Asp
Gln Phe Asp Cys
Gln Phe Met Ser
Gln Phe Ser Met
Gln His Asn Asn
Gln Met Ala Tyr
Gln Met Cys Met
Gln Met Phe Ser
Gln Met Met Cys
Gln Met Ser Phe
Gln Met Tyr Ala
Gln Asn His Asn
Gln Asn Asn His
Gln Ser Asp Tyr
Gln Ser Phe Met
Gln Ser Met Phe
Gln Ser Tyr Asp
Gln Val Cys Tyr
Gln Val Tyr Cys
Gln Tyr Ala Met
Gln Tyr Cys Val
Gln Tyr Asp Ser
Gln Tyr Met Ala
Gln Tyr Ser Asp
Gln Tyr Val Cys
Arg Cys Cys Met
Arg Cys Met Cys
Arg Met Cys Cys
Ser Asp Gln Tyr
Ser Asp Tyr Gln
Ser Glu Asn Tyr
Ser Glu Tyr Asn
Ser Phe Met Gln
Ser Phe Gln Met
Ser Gly Trp Tyr
Ser Gly Tyr Trp
Ser Met Phe Gln
Ser Met Gln Phe
Ser Asn Glu Tyr
Ser Asn Tyr Glu
Ser Gln Asp Tyr
Ser Gln Phe Met
Ser Gln Met Phe
Ser Gln Tyr Asp
Ser Trp Gly Tyr
Ser Trp Tyr Gly
Ser Tyr Asp Gln
Ser Tyr Glu Asn
Ser Tyr Gly Trp
Ser Tyr Asn Glu
Ser Tyr Gln Asp
Ser Tyr Trp Gly
Thr Cys Cys Trp
Thr Cys Trp Cys
Thr Asp Asn Tyr
Thr Asp Tyr Asn
Thr Phe Met Asn
Thr Phe Asn Met
Thr Met Phe Asn
Thr Met Asn Phe
Thr Asn Asp Tyr
Thr Asn Phe Met
Thr Asn Met Phe
Thr Asn Tyr Asp
Thr Trp Cys Cys
Thr Tyr Asp Asn
Thr Tyr Asn Asp
Val Cys Gln Tyr
Val Cys Tyr Gln
Val Gln Cys Tyr
Val Gln Tyr Cys
Val Tyr Cys Gln
Val Tyr Gln Cys
Trp Cys Cys Thr
Trp Cys Phe Gly
Trp Cys Gly Phe
Trp Cys Thr Cys
Trp Phe Cys Gly
Trp Phe Gly Cys
Trp Gly Cys Phe
Trp Gly Phe Cys
Trp Gly Ser Tyr
Trp Gly Tyr Ser
Trp Ser Gly Tyr
Trp Ser Tyr Gly
Trp Thr Cys Cys
Trp Tyr Gly Ser
Trp Tyr Ser Gly
Tyr Ala Met Gln
Tyr Ala Gln Met
Tyr Cys Ile Asn
Tyr Cys Leu Asn
Tyr Cys Asn Ile
Tyr Cys Asn Leu
Tyr Cys Gln Val
Tyr Cys Val Gln
Tyr Asp Asn Thr
Tyr Asp Gln Ser
Tyr Asp Ser Gln
Tyr Asp Thr Asn
Tyr Glu Asn Ser
Tyr Glu Ser Asn
Tyr Gly Ser Trp
Tyr Gly Trp Ser
Tyr Ile Cys Asn
Tyr Ile Asn Cys
Tyr Leu Cys Asn
Tyr Leu Asn Cys
Tyr Met Ala Gln
Tyr Met Gln Ala
Tyr Asn Cys Ile
Tyr Asn Cys Leu
Tyr Asn Asp Thr
Tyr Asn Glu Ser
Tyr Asn Ile Cys
Tyr Asn Leu Cys
Tyr Asn Ser Glu
Tyr Asn Thr Asp
Tyr Gln Ala Met
Tyr Gln Cys Val
Tyr Gln Asp Ser
Tyr Gln Met Ala
Tyr Gln Ser Asp
Tyr Gln Val Cys
Tyr Ser Asp Gln
Tyr Ser Glu Asn
Tyr Ser Gly Trp
Tyr Ser Asn Glu
Tyr Ser Gln Asp
Tyr Ser Trp Gly
Tyr Thr Asp Asn
Tyr Thr Asn Asp
Tyr Val Cys Gln
Tyr Val Gln Cys
Tyr Trp Gly Ser
Tyr Trp Ser Gly
O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->3)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol
O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->4)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol
sodium 3-[[4-(benzoylethylamino)-2-methylphenyl]azo]-4-hydroxynaphthalene-1-sulphonate
Arzoxifene hydrochloride
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
FMOC-3-CARBOXYMETHYL-1-PHENYL-1,3,8-TRIAZASPIRO[4 5]DECAN-4-ONE
2,6-bis(bis(4-fluorophenyl)methyl)-4-methylaniline
Cefetamet Pivoxil
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
(2-Amino-2-biphenylyl)(chloro)palladium - tris(2-methyl-2-propanyl)phosphine (1:1)
(E)-CefetametPivoxil
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
7,10,13-Tri(carboxymethyl)-5,15-dioxo-4,7,10,13,16-pentaaza-1,19-dithianonadecane
(E)-N-[(3aS,4R,5S,6S,7R,7aR)-4,6,7-trihydroxy-3a,4,5,6,7,7a-hexahydro-1,3-benzodioxol-5-yl]-3-[4-[(2S,3S,4S,5S)-5-acetyl-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyphenyl]-2-methylprop-2-enamide
(E)-3-[4-(5-acetyl-3,4-dihydroxyoxolan-2-yl)oxy-3-hydroxyphenyl]-2-methyl-N-(4,6,7-trihydroxy-3a,4,5,6,7,7a-hexahydro-1,3-benzodioxol-5-yl)prop-2-enamide
2-[(3-cyano-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-yl)thio]-N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]acetamide
O-[N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-serine
N(6)-{(2R)-2-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-2-[(2R,4S)-4-carboxy-5,5-dimethyl-1,3-thiazolidin-2-yl]acetyl}-L-lysine
(2R,4S)-2-[2-[[(5R)-5-amino-5-carboxypentyl]amino]-1-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-2-oxoethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
CGP71683 hydrochloride
CGP71683 hydrochloride is a competitive neuropeptide Y5 receptor antagonist with a Ki of 1.3 nM, and shows no obvious activity at Y1 receptor (Ki, >4000 nM) and Y2 receptor (Ki, 200 nM) in cell membranes.
CVT-11127
CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1]. CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1].
PPTN (hydrochloride)
PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity[1].